BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
2/2/2024 9:42:16 AM | Browse: 63 | Download: 88
 |
Received |
|
2023-10-06 13:56 |
|
Peer-Review Started |
|
2023-10-06 13:57 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2023-12-05 07:57 |
|
Revised |
|
2023-12-13 16:27 |
|
Second Decision |
|
2024-01-08 03:12 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2024-01-08 07:48 |
|
Articles in Press |
|
2024-01-08 07:48 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2024-01-11 02:54 |
|
Publish the Manuscript Online |
|
2024-02-02 09:42 |
| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Minireviews |
| Article Title |
Progress in the treatment of advanced hepatocellular carcinoma with immune combination therapy
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Di Pan, Hao-Nan Liu, Peng-Fei Qu, Xiao Ma, Lu-Yao Ma, Xiao-Xiao Chen, Yu-Qin Wang, Xiao-Bing Qin and Zheng-Xiang Han |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Zheng-Xiang Han, MD, Professor, Department of Oncology, The Affiliated Hospital of Xuzhou Medical University, No. 99 Huaihai West Road, Quanshan District, Xuzhou 221000, Jiangsu Province, China. cnhzxyq@163.com |
| Key Words |
Hepatocellular carcinoma; Immunotherapies; Immune checkpoint inhibitor; Clinical efficacy; Adverse reactions |
| Core Tip |
Although the incidence of hepatocellular carcinoma (HCC) in China is decreasing in all age groups, the overall treatment effect of a single immune checkpoint inhibitors regimen is often poor due to the obvious immunosuppressive features of HCC. Therefore, we review the current status, research progress and future directions of different immunotherapy strategies in HCC treatment. |
| Publish Date |
2024-02-02 09:42 |
| Citation |
Pan D, Liu HN, Qu PF, Ma X, Ma LY, Chen XX, Wang YQ, Qin XB, Han ZX. Progress in the treatment of advanced hepatocellular carcinoma with immune combination therapy. World J Gastrointest Oncol 2024; 16(2): 273-286 |
| URL |
https://www.wjgnet.com/1948-5204/full/v16/i2/273.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v16.i2.273 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
